ClinicalTrials.gg
RecruitingNCT05112705DETECTUpdated Sep 19, 2025

Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients

An interventional study of Proximal lower limb ultrasound in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by King Abdullah International Medical Research Center. Recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by King Abdullah International Medical Research Center · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The DETECT randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating DVT detection reduces the incidence of PE and lowers all-cause 90-day mortality. The primary outcome is 90-day all-cause mortality.

Read the detailed description

This is an open-label multicenter multinational randomized-controlled trial. All patients admitted to ICU will be screened within the first 48 hours of ICU admission for eligibility. Subjects who meet all criteria for enrollment will be randomized via a password-protected, secure website using a variable-size block concealed computer-generated randomization procedure. Patients will be allocated to twice weekly bilateral lower limb ultrasound or standard care (control) in a 1:1 ratio.

02

Conditions studied

  • Deep Vein Thrombosis
  • Pulmonary Embolism
03

In context

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

This study's planned enrollment of 1,800 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.

Browse Venous Thrombosis studies →

Lead sponsor

King Abdullah International Medical Research Center is the lead sponsor of 46 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Medical, surgical or trauma ICU patients ≥18 years old.
  2. Patients who are expected to stay in the ICU more than 2 calendar days (unlikely to be discharged out of ICU on the day of admission or on the next day).

Exclusion criteria

Exclusion Criteria

  1. Patients with DVT or PE diagnosed within the last year.
  2. Patients receiving chronic systemic anticoagulation.
  3. Patients who have received up to the time of ICU admission or are receiving therapeutic doses of anticoagulation with UFH, LMWH, or other anticoagulants.
  4. Inability or to obtain adequate ultrasound on the lower extremities (Burns in the lower extremities, lacerations, active skin infection, \& ischemic limb in the legs, large dressings in the thighs that prevent adequate ultrasounds OR amputated foot or leg on one or two sides)
  5. Patients with Inferior Vena Cava (IVC) Filter.
  6. Known or suspected pregnancy.
  7. Limitation of life support, \<7 days or palliative care.
  8. Previously enrolled in DETECT trial within the last 180 days.
  9. Enrolled in another trial for which co-enrolment is not approved.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,800 participants (estimated)

Study arms

  • Active comparator
    Ultrasound Group

    Patients will be receiving twice weekly proximal lower limb ultrasound

    Diagnostic Test: Proximal lower limb ultrasound

  • No intervention
    Control Group

    Proximal lower limb ultrasound will be performed as per the treating team discretion

Interventions

  • Diagnostic testProximal lower limb ultrasound

    Twice weekly proximal lower limb ultrasound

06

What researchers measure

Primary outcomes

  1. 90-day mortality

    Mortality 90 days post randomization

    Time frame: 90 days

Secondary outcomes

  1. Proximal DVT

    Lower limb proximal leg DVT, defined as partially or completely incompressible venous segment.

    Time frame: From randomization date to day 28 or ICU discharge whichever comes first

  2. Pulmonary Embolism

    Pulmonary embolism defined as definite PE (characteristic intraluminal filling defect on CT chest, high probability VQ scan or detected at autopsy); probable PE (moderate-high pretest, no test or a non-diagnostic test); possible PE (low pre-test probability, non-diagnostic test) or No PE (negative or normal test)

    Time frame: From randomization date and throughout hospital stay up to day 28

  3. Clinically important bleeding

    Fatal bleeding, symptomatic bleeding in critical organ or bleeding causing fall in hemoglobin, requiring transfusion or interventional radiology

    Time frame: From randomization date and throughout hospital stay up to day 90

Other outcomes

  1. Mechanical ventilation-free days

    Total number of days alive and free of mechanical ventilation within 28 days after randomization

    Time frame: 28 days

  2. Vasopressor-free days

    Total number of days alive and free of vasopressor use within 28 days after randomization

    Time frame: 28 days

  3. Days alive and out of hospital by day 90

    Days alive and out of the hospital at day 90 calculated by using the days from alive at hospital discharge to day 90

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Arabi YM, Alenezi F, Al-Hameed F, Al Humedi HI, Kharaba A, Alhazzani W, Alshahrani MSS, Algethamy H, Maghrabi K, Chalabi J, Ardah HI, Alahmari AM, AlQahtani RM, Ababtain AA, Al-Filfil WAM, Al-Fares AA, Buabbas SF, Bin Humaid F, Brembali MJ, Amer M, Sadat M, Al Tamimi A, AlHumaidan A, Alqahtani M, Al-Dawood A; Saudi Critical Care Trials Group. Diagnosing deep vein thrombosis early in critically ill patients (DETECT) trial: a protocol for a randomised controlled trial. BMJ Open. 2025 Oct 29;15(10):e104468. doi: 10.1136/bmjopen-2025-104468. PubMed 41161824 ↗

Individual participant data

Plan to share: Yes — The data supporting this study's findings will be available from the corresponding author upon reasonable request as per the regulations of King Abdullah International Medical Research Center (KAIMRC).

Time frame: After the publication of the main manuscript (Primary outcome analysis)

Access criteria: Proposal that describes planned analyses must be submitted along with a data sharing agreement

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2026, 36 months after the start.

Of 99 non-industry interventional studies with no phase under Venous Thrombosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 36 months is close to that.

Counting every sponsor, half of 117 studies reached it within 34 months; a quarter within 13 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 9, 2021
StartActual
Mar 21, 2023
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2026
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05112705
Lead sponsor
King Abdullah International Medical Research Center
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Mar 21, 2023
Primary completion
Mar 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 19, 2025

Study contacts

Yaseen M Arabi
Contact
yaseenarabi@yahoo.com
+966118011111 ext. 18899
Haifa Al Humeidi
Contact
alhumediha@mngha.med.sa
+966118011111 ext. 19589
Yaseen M Arabi
principal investigator · King Saud bin Abdulaziz University of Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion